X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2052) 2052
Newspaper Article (244) 244
Publication (170) 170
Magazine Article (141) 141
Newsletter (90) 90
Book Review (70) 70
Trade Publication Article (49) 49
Book Chapter (15) 15
Book / eBook (10) 10
Dissertation (5) 5
Web Resource (4) 4
Data Set (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Paper (1) 1
Reference (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aspirin (1805) 1805
humans (1478) 1478
index medicus (803) 803
female (676) 676
male (664) 664
aspirin - therapeutic use (603) 603
aged (570) 570
middle aged (531) 531
prevention (442) 442
risk factors (439) 439
stroke (372) 372
platelet aggregation inhibitors - therapeutic use (370) 370
cost-benefit analysis (361) 361
cardiovascular disease (331) 331
mortality (293) 293
adult (292) 292
risk (291) 291
medicine, general & internal (284) 284
research (259) 259
drug therapy (252) 252
clopidogrel (242) 242
cardiac & cardiovascular systems (239) 239
care and treatment (237) 237
aspirin - administration & dosage (232) 232
aspirin - economics (232) 232
pharmacology & pharmacy (229) 229
ticlopidine - analogs & derivatives (228) 228
health aspects (218) 218
analysis (213) 213
cardiovascular diseases (208) 208
treatment outcome (204) 204
heart attacks (203) 203
aged, 80 and over (195) 195
studies (195) 195
aspirin - adverse effects (189) 189
drug therapy, combination (189) 189
platelet aggregation inhibitors - economics (180) 180
low-dose aspirin (177) 177
patients (175) 175
pharmaceutical industry (173) 173
ticlopidine - therapeutic use (171) 171
anticoagulants (170) 170
therapy (170) 170
stroke - prevention & control (168) 168
warfarin (164) 164
medicine (156) 156
secondary prevention (156) 156
myocardial-infarction (154) 154
cardiovascular diseases - prevention & control (152) 152
medical research (152) 152
anticoagulants - therapeutic use (148) 148
cost-effectiveness (148) 148
management (144) 144
acute coronary syndromes (143) 143
dosage and administration (143) 143
disease (138) 138
atrial fibrillation (133) 133
usage (130) 130
drugs (128) 128
metaanalysis (127) 127
quality-adjusted life years (127) 127
coronary heart disease (126) 126
abridged index medicus (125) 125
cancer (124) 124
health risk assessment (124) 124
hypertension (124) 124
drug dosages (121) 121
time factors (121) 121
research article (120) 120
peripheral vascular disease (119) 119
clinical trials (118) 118
markov chains (118) 118
risk assessment (118) 118
platelet aggregation inhibitors - administration & dosage (117) 117
primary prevention (117) 117
ticlopidine - economics (116) 116
myocardial infarction (115) 115
socioeconomic factors (115) 115
randomized controlled trials as topic (112) 112
cardiology (111) 111
diabetes (109) 109
platelet aggregation inhibitors - adverse effects (108) 108
anti-inflammatory agents, non-steroidal - therapeutic use (107) 107
population (106) 106
retrospective studies (106) 106
prevalence (105) 105
nonsteroidal antiinflammatory drugs (104) 104
acute myocardial-infarction (103) 103
animals (103) 103
epidemiology (103) 103
ulcers (103) 103
health care sciences & services (102) 102
united states (99) 99
disease prevention (98) 98
medicine & public health (97) 97
trial (97) 97
antiplatelet therapy (94) 94
drug costs (94) 94
risk-factors (94) 94
hospitals (93) 93
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2497) 2497
German (23) 23
Spanish (19) 19
French (17) 17
Russian (6) 6
Portuguese (4) 4
Danish (3) 3
Dutch (2) 2
Hebrew (2) 2
Italian (2) 2
Japanese (2) 2
Serbian (2) 2
Swedish (2) 2
Czech (1) 1
Hungarian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Value in Health, ISSN 1098-3015, 2013, Volume 16, Issue 4, pp. 498 - 506
Abstract Objectives The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular... 
Internal Medicine | anticoagulants | cost-effectiveness | atrial fibrillation | cardiovascular | warfarin | MORTALITY | MANAGEMENT | ASPIRIN | PROPHYLAXIS | DABIGATRAN ETEXILATE | RISK-FACTOR | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Warfarin - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Atrial Fibrillation - economics | Benzimidazoles - administration & dosage | Time Factors | beta-Alanine - economics | Aged, 80 and over | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Cardiovascular Diseases - etiology | Administration, Oral | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Stroke - etiology | Hemorrhage - chemically induced | Drug Costs | Markov Chains | Age Factors | Anticoagulants - administration & dosage | Anticoagulants - economics | Thiophenes - administration & dosage | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Pyridones - administration & dosage | Thiophenes - economics | Cardiovascular Diseases - economics | Stroke - prevention & control | Hemorrhage - epidemiology | Morpholines - administration & dosage | Stroke - economics | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Pyrazoles - economics | Randomized Controlled Trials as Topic | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use
Journal Article
Journal Article
Cardiovascular Therapeutics, ISSN 1755-5914, 02/2013, Volume 31, Issue 1, pp. 45 - 52
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Journal Article
Clinical Cardiology, ISSN 0160-9289, 10/2017, Volume 40, Issue 10, pp. 789 - 796
Continuation of dual antiplatelet therapy (DAPT) beyond 1 year reduces late stent thrombosis and ischemic events after drug‐eluting stents (DES) but increases... 
Drug‐Eluting Stents | Clopidogrel | Dual Antiplatelet Therapy | Prolonged Treatment Duration | Cost‐Effectiveness | Acute Coronary Syndrome | Drug-Eluting Stents | Cost-Effectiveness | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | THROMBOSIS | BENEFIT | IMPLANTATION | SCORES | PRASUGREL | DURATION | Drug Costs | Platelet Aggregation Inhibitors - economics | Percutaneous Coronary Intervention - mortality | Acute Coronary Syndrome - economics | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Models, Economic | Hemorrhage - economics | Aspirin - administration & dosage | Percutaneous Coronary Intervention - instrumentation | Time Factors | Aspirin - adverse effects | Computer Simulation | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - economics | Ticlopidine - administration & dosage | Myocardial Infarction - economics | Aspirin - economics | Drug Therapy, Combination | Odds Ratio | Coronary Thrombosis - economics | Myocardial Infarction - etiology | Platelet Aggregation Inhibitors - adverse effects | Quality-Adjusted Life Years | Drug Administration Schedule | Risk Factors | Stroke - economics | Drug-Eluting Stents - economics | Treatment Outcome | Ticlopidine - analogs & derivatives | Disease-Free Survival | Stroke - etiology | Cost-Benefit Analysis | Acute Coronary Syndrome - diagnosis | Acute Coronary Syndrome - therapy | Coronary Thrombosis - etiology | Percutaneous Coronary Intervention - economics | Decision Trees | Hemorrhage - chemically induced | Monte Carlo Method | Percutaneous Coronary Intervention - adverse effects | Monte Carlo method | Aspirin | Analysis | Cardiac patients | Health care industry | Cost benefit analysis | Medical economics | Coronary heart disease | Stent (Surgery)
Journal Article
Journal Article
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2014, Volume 35, Issue 28, pp. 1897 - 1906
Journal Article
JAMA Internal Medicine, ISSN 2168-6106, 08/2017, Volume 177, Issue 8, pp. 1093 - 1101
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
Summary Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible... 
Internal Medicine | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Klinisk medicin | Clinical Medicine
Journal Article
BMJ, ISSN 0959-8138, 10/2011, Volume 343, Issue 7830, pp. 947 - 947
Journal Article